Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $455.79, giving the company a market capitalization of 115.77B. It carries a P/E multiple of 32.15.
During the trading session on 2025-12-21, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $460.40 and a low of $445.51. At a current price of $455.79, the stock is +2.3% higher than the low and still -1.0% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 5.54M, versus its average volume of 1.69M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
Vertex Pharmaceuticals recently reported new clinical data showing that all evaluable children aged 5–11 treated with CASGEVY achieved key endpoints in sickle c...
Key Points CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing ther...
Vertex Pharmaceuticals (VRTX) just delivered encouraging pediatric data for its gene editing therapy CASGEVY in sickle cell and beta thalassemia, and secured an...